Literature DB >> 20888928

Clinical, electrocardiographic, and electrophysiologic characteristics of patients with a fasciculoventricular pathway: the role of PRKAG2 mutation.

Eduardo Back Sternick1, Antonio Oliva, Luiz Márcio Gerken, Luiz Magalhães, Ricardo Scarpelli, Frederico Soares Correia, Silvia Rego, Oto Santana, Ramon Brugada, Hein J J Wellens.   

Abstract

BACKGROUND: The ECG, clinical, and electrophysiologic profiles of patients with a fasciculoventricular pathway are well described. Fasciculoventricular pathways occurring in the setting of glycogen storage cardiomyopathy possess unique features.
OBJECTIVE: The purpose of this study was to compare the clinical, ECG, and electrophysiologic characteristics of patients with a fasciculoventricular pathway, with or without glycogen storage cardiomyopathy.
METHODS: Two groups of patients with a fasciculoventricular pathway were compared: group A consisted of 10 patients with the PRKAG2 mutation (Arg302gln), and group B consisted of 9 patients without the mutation.
RESULTS: Thirty percent of group A patients had left ventricular hypertrophy, and none had an additional accessory pathway. Group B patients had no structural heart disease, and 33% had an additional accessory pathway. Group A patients had a slower resting heart rate (56 ± 7 vs 75 ± 10 bpm, P <0.0001), a wider QRS complex (0.15 ± 0.01 vs 0.11 ± 0.02 ms, P = .0004), and a longer HV interval (34 ± 1 vs 25 ± 3 ms, P = .0003). During long-term follow-up, 50% of group A patients developed complete AV block versus none in group B. Eighty percent of group A patients developed atrial flutter and/or atrial fibrillation. No Group B patient had any arrhythmia during follow-up after successful ablation of additional arrhythmia circuits. No sustained ventricular arrhythmia was induced in any patient from either group.
CONCLUSION: Patients with a fasciculoventricular pathway associated with the PRKAG2 mutation have distinct clinical, ECG, and electrophysiologic profiles and should be correctly identified because of their ominous long-term prognosis. Patients without the mutation have an excellent arrhythmia-free prognosis after treatment of additional circuits.
Copyright © 2011 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20888928     DOI: 10.1016/j.hrthm.2010.09.081

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  18 in total

Review 1.  Clinical Spectrum of PRKAG2 Syndrome.

Authors:  Andrea Giuseppe Porto; Francesca Brun; Giovanni Maria Severini; Pasquale Losurdo; Enrico Fabris; Matthew R G Taylor; Luisa Mestroni; Gianfranco Sinagra
Journal:  Circ Arrhythm Electrophysiol       Date:  2016-01

2.  European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases.

Authors:  Arthur A M Wilde; Christopher Semsarian; Manlio F Márquez; Alireza Sepehri Shamloo; Michael J Ackerman; Euan A Ashley; Back Sternick Eduardo; Héctor Barajas-Martinez; Elijah R Behr; Connie R Bezzina; Jeroen Breckpot; Philippe Charron; Priya Chockalingam; Lia Crotti; Michael H Gollob; Steven Lubitz; Naomasa Makita; Seiko Ohno; Martín Ortiz-Genga; Luciana Sacilotto; Eric Schulze-Bahr; Wataru Shimizu; Nona Sotoodehnia; Rafik Tadros; James S Ware; David S Winlaw; Elizabeth S Kaufman; Takeshi Aiba; Andreas Bollmann; Jong-Il Choi; Aarti Dalal; Francisco Darrieux; John Giudicessi; Mariana Guerchicoff; Kui Hong; Andrew D Krahn; Ciorsti Mac Intyre; Judith A Mackall; Lluís Mont; Carlo Napolitano; Pablo Ochoa Juan; Petr Peichl; Alexandre C Pereira; Peter J Schwartz; Jon Skinner; Christoph Stellbrink; Jacob Tfelt-Hansen; Thomas Deneke
Journal:  J Arrhythm       Date:  2022-05-31

3.  European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases.

Authors:  Arthur A M Wilde; Christopher Semsarian; Manlio F Márquez; Alireza Sepehri Shamloo; Michael J Ackerman; Euan A Ashley; Eduardo Back Sternick; Héctor Barajas-Martinez; Elijah R Behr; Connie R Bezzina; Jeroen Breckpot; Philippe Charron; Priya Chockalingam; Lia Crotti; Michael H Gollob; Steven Lubitz; Naomasa Makita; Seiko Ohno; Martín Ortiz-Genga; Luciana Sacilotto; Eric Schulze-Bahr; Wataru Shimizu; Nona Sotoodehnia; Rafik Tadros; James S Ware; David S Winlaw; Elizabeth S Kaufman; Takeshi Aiba; Andreas Bollmann; Jong Il Choi; Aarti Dalal; Francisco Darrieux; John Giudicessi; Mariana Guerchicoff; Kui Hong; Andrew D Krahn; Ciorsti MacIntyre; Judith A Mackall; Lluís Mont; Carlo Napolitano; Juan Pablo Ochoa; Petr Peichl; Alexandre C Pereira; Peter J Schwartz; Jon Skinner; Christoph Stellbrink; Jacob Tfelt-Hansen; Thomas Deneke
Journal:  Europace       Date:  2022-09-01       Impact factor: 5.486

4.  Identification of a novel de novo mutation associated with PRKAG2 cardiac syndrome and early onset of heart failure.

Authors:  Yang Liu; Rong Bai; Lin Wang; Cuntai Zhang; Ruifu Zhao; Deli Wan; Xinshan Chen; Gabriel Caceres; Daniel Barr; Hector Barajas-Martinez; Charles Antzelevitch; Dan Hu
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

5.  Mammalian γ2 AMPK regulates intrinsic heart rate.

Authors:  Arash Yavari; Mohamed Bellahcene; Annalisa Bucchi; Syevda Sirenko; Katalin Pinter; Neil Herring; Julia J Jung; Kirill V Tarasov; Emily J Sharpe; Markus Wolfien; Gabor Czibik; Violetta Steeples; Sahar Ghaffari; Chinh Nguyen; Alexander Stockenhuber; Joshua R St Clair; Christian Rimmbach; Yosuke Okamoto; Dongmei Yang; Mingyi Wang; Bruce D Ziman; Jack M Moen; Daniel R Riordon; Christopher Ramirez; Manuel Paina; Joonho Lee; Jing Zhang; Ismayil Ahmet; Michael G Matt; Yelena S Tarasova; Dilair Baban; Natasha Sahgal; Helen Lockstone; Rathi Puliyadi; Joseph de Bono; Owen M Siggs; John Gomes; Hannah Muskett; Mahon L Maguire; Youlia Beglov; Matthew Kelly; Pedro P N Dos Santos; Nicola J Bright; Angela Woods; Katja Gehmlich; Henrik Isackson; Gillian Douglas; David J P Ferguson; Jürgen E Schneider; Andrew Tinker; Olaf Wolkenhauer; Keith M Channon; Richard J Cornall; Eduardo B Sternick; David J Paterson; Charles S Redwood; David Carling; Catherine Proenza; Robert David; Mirko Baruscotti; Dario DiFrancesco; Edward G Lakatta; Hugh Watkins; Houman Ashrafian
Journal:  Nat Commun       Date:  2017-11-02       Impact factor: 14.919

6.  A novel PRKAG2 mutation in a Chinese family with cardiac hypertrophy and ventricular pre-excitation.

Authors:  Kun-Qi Yang; Chao-Xia Lu; Ying Zhang; Yan-Kun Yang; Jia-Cheng Li; Tian Lan; Xu Meng; Peng Fan; Tao Tian; Lin-Ping Wang; Ya-Xin Liu; Xue Zhang; Xian-Liang Zhou
Journal:  Sci Rep       Date:  2017-05-25       Impact factor: 4.379

7.  Wolff-Parkinson-White Syndrome with Ventricular Hypertrophy in a Brazilian Family.

Authors:  Lenises de Paula van der Steld; Oscar Campuzano; Alexandra Pérez-Serra; Mabel Moura de Barros Zamorano; Selma Sousa Matos; Ramon Brugada
Journal:  Am J Case Rep       Date:  2017-07-10

8.  Fasciculoventricular bypass tracts: Electrocardiographic and electrophysiologic features.

Authors:  Dimitrios Asvestas; George Bazoukis; Panagiotis Mililis; Stelios Dragasis; Athanasia Megarisiotou; Konstantinos Vlachos; Antonios Sideris; Michael Efremidis; Konstantinos P Letsas
Journal:  J Arrhythm       Date:  2020-05-08

9.  Cardiovascular magnetic resonance findings in patients with PRKAG2 gene mutations.

Authors:  Pauli Pöyhönen; Anita Hiippala; Laura Ollila; Touko Kaasalainen; Helena Hänninen; Tiina Heliö; Jonna Tallila; Catalina Vasilescu; Sari Kivistö; Tiina Ojala; Miia Holmström
Journal:  J Cardiovasc Magn Reson       Date:  2015-10-24       Impact factor: 5.364

10.  How Echocardiographic Deformation Indices Can Distinguish Different Types of Left Ventricular Hypertrophy.

Authors:  José Luiz Barros Pena; Wander Costa Santos; Stanley de Almeida Araújo; Glauber Monteiro Dias; Eduardo Back Sternick
Journal:  Arq Bras Cardiol       Date:  2018-11       Impact factor: 2.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.